Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it is conducting a second Phase IIb monotherapy trial to further study the effects of SP-01A for 28 days. This 28-day monotherapy study will allow Samaritan to gain longer-term data on SP-01A as an oral entry inhibitor and possible candidate to treat HIV drug resistance patients.
